This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letscher-Bru, V.
Right arrow Articles by Herbrecht, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letscher-Bru, V.
Right arrow Articles by Herbrecht, R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2002, p. 1100-1102, Vol. 40, No. 3
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.3.1100-1102.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Successful Outcome of Treatment of a Disseminated Infection Due to Fusarium dimerum in a Leukemia Patient

Valérie Letscher-Bru,1 France Campos,2 Jocelyn Waller,1 Raoul Randriamahazaka,2 Ermanno Candolfi,1 and Raoul Herbrecht2*

Institut de Parasitologie et de Pathologie Tropicale, Faculté de Médecine, 67000 Strasbourg,1 Département d'Hématologie et d'Oncologie, Hôpital de Hautepierre, 67098 Strasbourg, France2

Received 13 September 2001/ Returned for modification 6 November 2001/ Accepted 24 December 2001


arrow
ABSTRACT
 
We report the first case of proven disseminated infection due to Fusarium dimerum associated with a favorable outcome in a patient with acute leukemia and prolonged neutropenia. The patient presented persistent fever, multiple necrotic skin lesions, and bilateral pneumopathy. F. dimerum was first isolated from three blood cultures and then from a skin biopsy and a mouth wash. Microscopy of positive blood cultures showed hyphae with phialides and few curved unicellular and some rare bicellular phialoconidia, permitting immediate presumptive identification of the genus Fusarium. The patient failed to respond to conventional amphotericin B but recovered after treatment was switched to amphotericin B-lipid complex and neutrophil recovery.


arrow
TEXT
 
Fusarium species are common soil saprophytes and plant pathogens. In humans, several species have been recognized as agents of superficial infections (keratitis, cutaneous infections, onychomycosis, and infection of wounds or burns) (8). In recent years, deep-seated and disseminated infections have been increasingly described in immunocompromised patients, especially in neutropenic patients (3, 8, 16). The prognosis is very poor, and death occurs in up to 70% of the cases despite antifungal therapy (3, 13, 16). The Fusarium species most frequently involved in human infections are Fusarium solani, F. oxysporum and F. moniliforme (8). F. dimerum has been involved in superficial infections (19, 24) but has been involved only rarely in invasive infections (2, 4).

Case report. A 61-year-old woman was admitted in December 1998 for relapse of acute lymphoblastic leukemia. Sequential induction chemotherapy was started and resulted in prolonged aplasia and severe mucositis. Antibacterial gut decontamination and antifungal prophylaxis with fluconazole (oral suspension; 150 mg/day) were instituted. The patient experienced two episodes of bacteremia that were treated with piperacillin, tazocillin, and vancomycin.

On day 32 of aplasia, the patient became febrile again (38.8°C). She was still severely neutropenic (neutrophil count, 0/µl) despite the administration of granulocyte colony-stimulating factor, and the mucositis had not completely disappeared. A chest X-ray revealed a left basal infiltrate. Three separate blood samples drawn into fungal medium vials (Mycosis-IC/F; Becton Dickinson, New York, N.Y.) grew F. dimerum. Two days later, multiple ecchymotic papules measuring 0.5 to 1 cm in diameter and sensitive to palpation appeared on the right thigh and on the inside of the left knee.

Fluconazole therapy was discontinued, and intravenous amphotericin B therapy (1 mg/kg/day) was initiated. Gomori methenamine silver staining of a skin biopsy showed rare, irregular, hyaline, septate, and 45°-branching hyphae, and culture on Sabouraud's glucose agar at 27°C grew F. dimerum within 5 days. A mouth wash culture also grew F. dimerum. Only one sputum sample could be obtained, and it was culture negative. Bronchoalveolar lavage was not considered. The central venous line was removed, and it was culture negative. The fingernails and toenails were normal.

After 5 days of conventional amphotericin B therapy, blood cultures were negative but the fever persisted (39.8°C). The skin lesions became nodular and necrotic, and new lesions appeared (Fig. 1). Pulmonary infection extended to the left upper lung and to the right lung. Neutropenia persisted (neutrophil count, 150/µl). Conventional amphotericin B was replaced with amphotericin B-lipid complex (ABLC; 5.3 mg/kg/day). After 4 days, the patient recovered from neutropenia (neutrophil count, 610/µl) and became afebrile. The skin lesions regressed slowly and disappeared within 1 month. The pneumopathy transiently worsened concurrently with granulocyte recovery and then gradually improved.



View larger version (116K):
[in this window]
[in a new window]
  		FIG. 1. Multiple necrotic skin nodules located on both legs.

ABLC therapy was continued for 25 days with a cumulative dose of 7,500 mg (132 mg/kg). Apart from moderate hypokalemia, the treatment was well tolerated. Renal function remained normal (baseline, 76 µmol/liter; final serum creatinine, 51 µmol/liter). The patient was discharged with no sign of infection and in complete hematological remission. The patient suffered from a leukemia relapse 7 months later and again received induction chemotherapy. She experienced no relapse of fusariosis.

Mycological findings. F. dimerum was first isolated from three blood cultures and then from one skin biopsy and one mouth wash.

Blood cultures were drawn into specific fungal medium vials (Mycosis-IC/F; Becton Dickinson). Fungal growth was detected after 3 days of incubation at 35°C in the Bactec 9240 system (Becton Dickinson). Microscopic examination showed hyaline, septate, branched hyphae with phialides and a few curved unicellular and some rare bicellular phialoconidia, allowing initial presumptive identification of the genus Fusarium (Fig. 2).



View larger version (152K):
[in this window]
[in a new window]
  		FIG. 2. Microscopy of a positive blood culture showing hyaline, septate, branched hyphae with phialides, phialoconidia, and bicellular curved macroconidia.

A definitive diagnosis of F. dimerum was obtained after subculture on Sabouraud's glucose agar and potato dextrose agar media incubated for 14 days at 27°C. Species identification was based on morphological criteria after subculture. The colonies grew slowly, attaining a diameter of 2 cm after 5 days. The colonies appeared moist and orange with a reverse turning to orange. Microscopic examination showed hyaline septate hyphae with swollen monophialides (10 to 20 by 4 to 5 µm) arising from the mycelium or from simple or occasionally branched short conidiophores. Phialides produced numerous curved hyaline macroconidia (5 to 23 by 2 to 4 µm), mostly one septate and in rare cases two septate (Fig. 3). Microconidia were absent or indistinguishable from the young macroconidia. After 7 days, spherical smooth-walled chlamydospores appeared, mostly intercalate, sometimes terminal.



View larger version (139K):
[in this window]
[in a new window]
  		FIG. 3. Seven-day-old culture showing typical bicellular curved conidia produced by swollen monophialides.

The F. dimerum strain was tested for antifungal susceptibility by the E-Test (AB Biodisk, Solna, Sweden) method. The MICs of amphotericin B and fluconazole were, respectively, 0.38 µg/ml and greater than 256 µg/ml.

Invasive fusariosis is an increasingly life-threatening complication in patients with hematological malignancies, in hematopoietic stem cell transplant recipients, and, to a lesser extent, in solid-organ transplant recipients (3, 11, 13, 20). Infection usually occurs during profound and prolonged neutropenia. The most frequent species are F. solani, F. oxysporum, and F. moniliforme (3, 8).

Here, we report the first case of a proven disseminated infection due to F. dimerum associated with a favorable outcome. This species is a common agent of keratitis and superficial infections (8, 19, 24). Only two cases of deep infection caused by F. dimerum have been reported, and both were fatal. Camin et al. described a case of endocarditis involving a native aortic valve after coronary artery bypass grafting in an immunocompetent patient (4). Despite valve replacement and combined antifungal therapy with amphotericin B and flucytosine followed by itraconazole, the aortic vegetations recurred and the patient died 8 weeks after surgery. Blood cultures were negative throughout the course of the infection. Austen et al. observed a disseminated infection in an acute lymphoblastic leukemia patient (2). The patient died despite neutrophil recovery and conventional amphotericin B treatment.

Fusarium species are widely present in the environment. It has been suggested that airborne conidia might invade the respiratory tract with primary lung or sinus localization or might be inoculated through a skin disruption such as an indwelling central venous catheter, a wound, or a burn (3). Dissemination from preexisting onychomycosis or gastrointestinal colonization has also been described (3, 11). In our case, the portal of entry remains unclear. The culture of the central venous catheter was negative, and no primary cutaneous lesion or onychomycosis could be demonstrated. We could hypothesize two possible portals of entry. The first is the oropharyngeal mucosa, as the patient experienced severe mucositis and the pathogen was found in a mouth wash fluid culture. The second is the respiratory tract, since pulmonary signs were present at the onset of fever.

In contrast to aspergillosis, disseminated fusariosis is associated with isolation of the fungus in the bloodstream in 50% of cases (3, 10). In our patient, three blood cultures drawn into fungus-specific medium were positive while simultaneous blood samples drawn into bacterial medium remained negative. Moreover, microscopy of the positive blood culture showed hyaline septate branched hyphae with phialides and a few curved unicellular and some rare bicellular phialoconidia that allowed immediate presumptive identification of the genus Fusarium. This confirms the advantage of specific fungal media over standard microbiological media in patients with invasive fungal infections.

The prognosis of invasive fusariosis is poor, with a mortality rate reaching 70 to 80% in disseminated cases (3, 11, 16). Systemic antifungal agents demonstrate poor efficiency in vitro and in vivo (15, 17, 18). Among these agents, amphotericin B seems to have the highest in vitro activity, with about 50% of isolates being susceptible to this drug (11) and MICs for 90% of the strains tested ranging from 1 to 4 µg/ml (15, 17, 18). Unfortunately the correlation between in vitro values and clinical efficacy is low and many patients remain unresponsive to treatment despite in vitro susceptibility. Lipid formulations of amphotericin B seem to be more effective in vivo than conventional amphotericin B, with a response rate of 82% for ABLC in a study of 11 cases of fusariosis, including five disseminated infections (23). Several individual case reports of invasive fusariosis also favor the use of a lipid formulation of amphotericin B (5, 6, 7, 9, 14, 21).

The best prognosis factor remains recovery from neutropenia, as shown by Martino et al. (11). The survival rate was 76% in patients who recovered from neutropenia, as opposed to 6% in patients with persistent neutropenia. The use of hematopoietic growth factors appears to be mandatory in neutropenic patients with invasive fusariosis, as well as for other invasive fungal infections (22).

New azoles, including voriconazole, posaconazole, and ravuconazole, might be promising and provide alternative therapy (22). In vitro studies are encouraging, but the clinical data are insufficient to allow firm conclusions to be drawn (1, 12).

In conclusion, the case we report is remarkable due to the unusual species involved, the successful outcome despite extensive dissemination of the disease, and the immediate presumptive identification of the genus Fusarium due to sporulation of the fungus in blood culture vials.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Département d'Hématologie et d'Oncologie, Hôpital de Hautepierre, Ave. Molière, 67098 Strasbourg, France. Phone: 33 3 88 12 76 88. Fax: 33 3 88 12 76 81. E-mail: raoul.herbrecht{at}chru-strasbourg.fr. Back


arrow
REFERENCES
 
    1
  1. Arikan, S., M. Lozano-Chiu, V. Paetznick, S. Nangia, and J. H. Rex. 1999. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol. 37:3946-3951.[Abstract/Free Full Text]
    2. 2
  2. Austen, B., H. McCarthy, B. Wilkins, A. Smith, and A. Duncombe. 2001. Fatal disseminated Fusarium infection in acute lymphoblastic leukaemia in complete remission. J. Clin. Pathol. 54:488-490.[Abstract/Free Full Text]
    3. 3
  3. Boutati, E. I., and E. J. Anaissie. 1997. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 90:999-1008.[Abstract/Free Full Text]
    4. 4
  4. Camin, A. M., C. Michelet, T. Langanay, C. de Place, S. Chevrier, E. Gueho, and C. Guiguen. 1999. Endocarditis due to Fusarium dimerum four years after coronary artery bypass grafting. Clin. Infect. Dis. 28:150.[Medline]
    5. 5
  5. Cofrancesco, E., C. Boschetti, M. A. Viviani, C. Bargiggia, A. M. Tortorano, M. Cortellaro, and C. Zanussi. 1992. Efficacy of liposomal amphotericin B (AmBisome) in the eradication of Fusarium infection in a leukaemic patient. Haematologica 77:280-283.[Medline]
    6. 6
  6. Ellis, M. E., H. Clink, D. Younge, and B. Hainau. 1994. Successful combined surgical and medical treatment of Fusarium infection after bone marrow transplantation. Scand. J. Infect. Dis. 26:225-228.[Medline]
    7. 7
  7. Engelhard, D., A. Eldor, I. Polacheck, I. Hardan, D. Ben-Yehuda, S. Amselem, I. F. Salkin, G. Lopez-Berestein, T. Sacks, E. A. Rachmilewitz, et al. 1993. Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex. Leuk. Lymphoma 9:385-392.[Medline]
    8. 8
  8. Guarro, J., and J. Gene. 1995. Opportunistic fusarial infections in humans. Eur. J. Clin. Microbiol. Infect. Dis. 14:741-754.[CrossRef][Medline]
    9. 9
  9. Guinvarc'h, A., L. Guilbert, A. Marmorat-Khuong, V. Lavarde, P. Chevalier, C. Amrein, R. Guillemain, and A. Berrebi. 1998. Disseminated Fusarium solani infection with endocarditis in a lung transplant recipient. Mycoses 41:59-61.[Medline]
    10. 10
  10. Hennequin, C., V. Lavarde, J. L. Poirot, M. Rabodonirina, A. Datry, S. Aractingi, J. Dupouy-Camet, D. Caillot, F. Grange, L. Kures, O. Morin, B. Lebeau, S. Bretagne, C. Guigen, D. Basset, and R. Grillot. 1997. Invasive Fusarium infections: a retrospective survey of 31 cases. J. Med. Vet. Mycol. 35:107-114.[Medline]
    11. 11
  11. Martino, P., R. Gastaldi, R. Raccah, and C. Girmenia. 1994. Clinical patterns of Fusarium infections in immunocompromised patients. J. Infect. 28(Suppl. 1):7-15.
    12. 12
  12. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, Jr., and M. G. Rinaldi. 1998. In vitro activity of voriconazole against selected fungi. Med. Mycol. 36:239-242.[CrossRef][Medline]
    13. 13
  13. Musa, M. O., A. Al Eisa, M. Halim, E. Sahovic, M. Gyger, N. Chaudhri, F. Al Mohareb, P. Seth, M. Aslam, and M. Aljurf. 2000. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br. J. Haematol. 108:544-548.[CrossRef][Medline]
    14. 14
  14. Patterson, T. S., L. L. Barton, Z. M. Shehab, and J. J. Hutter. 1996. Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Clin. Pediatr 35:257-260.[Abstract/Free Full Text]
    15. 15
  15. Pujol, I., J. Guarro, J. Gene, and J. Sala. 1997. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J. Antimicrob. Chemother. 39:163-167.[Abstract/Free Full Text]
    16. 16
  16. Rabodonirina, M., M. A. Piens, M. F. Monier, E. Gueho, D. Fiere, and M. Mojon. 1994. Fusarium infections in immunocompromised patients: case reports and literature review. Eur. J. Clin. Microbiol. Infect. Dis. 13:152-161.[CrossRef][Medline]
    17. 17
  17. Reuben, A., E. Anaissie, P. E. Nelson, R. Hashem, C. Legrand, D. H. Ho, and G. P. Bodey. 1989. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob. Agents Chemother. 33:1647-1649.[Abstract/Free Full Text]
    18. 18
  18. Rotowa, N. A., H. J. Shadomy, and S. Shadomy. 1990. In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses 33:203-211.[Medline]
    19. 19
  19. Sallaber, S., G. Lori, and I. Galeppi. 1999. Keratomycosis by Fusarium dimerum. Enferm. Infecc. Microbiol. Clin. 17:146-147.[Medline]
    20. 20
  20. Sampathkumar, P., and C. V. Paya. 2001. Fusarium infection after solid-organ transplantation. Clin. Infect. Dis. 32:1237-1240.[CrossRef][Medline]
    21. 21
  21. Viviani, M. A., E. Cofrancesco, C. Boschetti, A. M. Tortorano, and M. Cortellaro. 1991. Eradication of Fusarium infection in a leukopenic patient treated with liposomal amphotericin B. Mycoses 34:255-256.[Medline]
    22. 22
  22. Walsh, T. J., and A. H. Groll. 1999. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant. Infect. Dis. 1:247-261.[CrossRef][Medline]
    23. 23
  23. Walsh, T. J., J. W. Hiemenz, N. L. Seibel, J. R. Perfect, G. Horwith, L. Lee, J. L. Silber, M. J. DiNubile, A. Reboli, E. Bow, J. Lister, and E. J. Anaissie. 1998. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26:1383-1396.[Medline]
    24. 24
  24. Zapater, R. C., and A. Arrechea. 1975. Mycotic keratitis by Fusarium. A review and report of two cases. Ophthalmologica 170:1-12.[Medline]

Journal of Clinical Microbiology, March 2002, p. 1100-1102, Vol. 40, No. 3
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.3.1100-1102.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Azor, M., Gene, J., Cano, J., Manikandan, P., Venkatapathy, N., Guarro, J. (2009). Less-Frequent Fusarium Species of Clinical Interest: Correlation between Morphological and Molecular Identification and Antifungal Susceptibility. J. Clin. Microbiol. 47: 1463-1468 [Abstract] [Full Text]  
  • Schroers, H.-J., O'Donnell, K., Lamprecht, S. C., Kammeyer, P. L., Johnson, S., Sutton, D. A., Rinaldi, M. G., Geiser, D. M., Summerbell, R. C. (2009). Taxonomy and phylogeny of the Fusarium dimerum species group.. Mycologia 101: 44-70 [Abstract] [Full Text]  
  • Nucci, M., Anaissie, E. (2007). Fusarium Infections in Immunocompromised Patients. Clin. Microbiol. Rev. 20: 695-704 [Abstract] [Full Text]  
  • Hageskal, G., Knutsen, A. K., Gaustad, P., de Hoog, G. S., Skaar, I. (2006). Diversity and Significance of Mold Species in Norwegian Drinking Water. Appl. Environ. Microbiol. 72: 7586-7593 [Abstract] [Full Text]  
  • Spellberg, B., Schwartz, J., Fu, Y., Avanesian, V., Adler-Moore, J., Edwards, J. E. Jr, Ibrahim, A. S. (2006). Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 58: 973-979 [Abstract] [Full Text]  
  • Fricker-Hidalgo, H., Lebeau, B., Pelloux, H., Grillot, R., Horvath, L. L., Hospenthal, D. R. (2004). Use of the BACTEC 9240 System with Mycosis-IC/F Blood Culture Bottles for Detection of Fungemia. J. Clin. Microbiol. 42: 1855-1856 [Full Text]  
  • Durand-Joly, I., Alfandari, S., Benchikh, Z., Rodrigue, M., Espinel-Ingroff, A., Catteau, B., Cordevant, C., Camus, D., Dei-Cas, E., Bauters, F., Delhaes, L., De Botton, S. (2003). Successful Outcome of Disseminated Fusarium Infection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia. J. Clin. Microbiol. 41: 4898-4900 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letscher-Bru, V.
Right arrow Articles by Herbrecht, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letscher-Bru, V.
Right arrow Articles by Herbrecht, R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»